Istituto Luso Farmaco D'italia S.p.a.

A. Menarini Industrie Farmaceutiche Riunite S.r.l.

Menarini Ricerche S.p.a.

Laboratori Guidotti S.p.a.

Malesci Istituto Farmacobiologico S.p.a.

A. Menatini Industrie Farmaceutiche

Laura Quartara

Carlo Alberto Maggi

Alessandro Giolitti

Cristina Rossi

Patrizia Felicetti

Christopher Ingo Fincham

Federico Maria Arcamone

Danilo Giannotti

Carlo Pedone

Sandro Giuliani

Vincenzo Pavone

Angelina Lombardi

Federico Calvani

Fernando Catrambone

Rosa Terracciano

Disclosed are pharmaceutical compositions containing, as the active ingredients, a mixture of a hyaluronic acid polymer with a bradykinin B2 receptor antagonist. Said compositions have proved especially effective in the treatment of degenerative joint diseases such as osteoarthritis using intra-articular injections.

Pharmaceutical compositions containing bradykinin antagonists and hyaluronic acid, and uses thereof

Non-peptide compounds having activity as selective antagonists of bradykinin (BK) B2 receptor are disclosed. The compounds have the general formula (I) in which R is hydrogen or methyl; W is a single bond or an oxygen atom; n=3; X is hydrogen or a &#x2014;NRRamino group in which Rand Rcan be independently hydrogen or a group which is methyl, ethyl, n-propyl, or isopropyl; Y is a &#x2014;NRRRquaternary ammonium group in which RRRcan be independently a group which is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, or n-pentyl; and the enantiomers and enantiomeric mixtures thereof. Pharmaceutical compositions containing these compounds and methods of using the compounds to treat patients having conditions, disorders or diseases involving activation of bradykinin B2 receptors are also disclosed.

Non-peptide bradykinin antagonists and pharmaceutical compositions therefrom

Non-peptide compounds of formula (I) having activity as specific antagonists of bradykinin (BK) B2 receptor. The compounds are chemically characterized by the presence of an alpha, alpha-disubstituted amino acid at least one amino group, free or salified, or the corresponding ammonium quaternary salt. These BK receptor antagonists are a novel class of medicaments which can be used in all the disorders in which the receptors are involved.

Basic non-peptide bradykinin antagonists and pharmaceutical compositions therefrom

This invention relates to novel compounds of general formula (I): ##STR1## and to pharmaceutical compositions containing them.

Bicyclic tachykinins antagonists, preparation thereof and their use in

Tachyikinin antagonist compounds of the general formula: ##STR1## are described where: X1, X2, X3, X4, X5, and X6 are identical or different and are --NR'--CO-- or --CO--NR'--, where R' is H or C.sub.1-3 alkyl;

Tachiquinine antagonist tricyclic compounds, preparation of same and

Growing community of inventors

Florence, Italy

Laura Quartara